Predictors of symptomatic laboratory-confirmed SARS-COV-2 reinfection

Efrén Murillo-Zamora^{1,2}, Carlos M. Hernandez-Suarez³, Agustin Lugo-Radillo⁴, Felipe Aguilar-Sollano⁵, and Oliver Mendoza-Cano^{5*}

1 Departamento de Epidemiología, Unidad de Medicina Familiar No. 19, Instituto Mexicano del Seguro Social, Av. Javier Mina 301, Col. Centro, C.P. 28000, Colima, Colima, México. Tel. +52 (312) 3163770, E-mail efren.murilloza@imss.gob.mx

2 Facultad de Medicina, Universidad de Colima, Av. Universidad 333, Col. Las Víboras, C.P. 28040, Colima, Colima, México

3 Facultad de Ciencias, Universidad de Colima, Bernal Díaz del Castillo 340, Col. Villas San Sebastián, C.P. 28045, Tel. +52 (312) 3161135, E-mail carlosmh@mac.com

4 CONACYT-Facultad de Medicina y Cirugía, Universidad Autónoma Benito Juárez de Oaxaca, Ex Hacienda de Aguilera S/N, Carretera a San Felipe del Agua, Oaxaca 68020, Oaxaca, Mexico, Email: alugora@conacyt.mx

5 Programa de Maestría en Ciencias Médicas, Universidad de Colima, Av. Universidad 333, Col. Las Víboras, C.P. 28040, Colima, Colima, México. Tel. +52 (312) 3120212, E-mail qfaguilar1@gmail.com

6 Facultad de Ingeniería Civil, Universidad de Colima, km. 9 carretera Colima-Coquimatlán, Coquimatlán, C.P. 28400, Colima, México. Tel. +52 (312) 3161167, E-mail oliver@ucol.mx

* **Corresponding author**

Abstract

Objective: To identify factors predicting symptomatic laboratory-positive SARS-COV-2 reinfection.

Method: We conducted a nationwide retrospective cohort study and data from 99,993 confirmed cases of COVID-19 were analyzed.

Results: The overall risk of reinfection (28 or more elapsed days between both episodes onset) was 0.21%, and older subjects and those with mild primary disease were at reduced risk of reinfection. Healthcare workers and immunosuppressed or renal patients had at greater risk of SARS-COV-2 reinfection.

Conclusions: If replicated in other populations, these results may be useful to prioritize efforts focusing on the reduction of SARS-COV-2 spread and the related burden.

Keywords: COVID-19; Severe Acute Respiratory Syndrome Coronavirus 2; Health Personnel; Risk Reduction Behavior.

Introduction

The COVID-19 (coronavirus disease 2019) by SARS-COV-2 (severe acute respiratory coronavirus 2) pandemic is a complex phenomenon and reinfection is one of the many ongoing related debates [1]. Current knowledge regarding factors predicting the SARS-COV-2 reinfection risk is scarce, and it has significant implications in public health policies, including vaccination strategies and relaxation of social distancing measures [2].

The social and economic burden of the COVID-19 pandemic in Mexico has been high, and by September 24, more than 715 thousand confirmed cases and nearly 80 thousand deaths had been registered [3]. This study aimed to evaluate factors predicting SARS-COV-2 symptomatic reinfection in a large and nationwide cohort of laboratory-confirmed COVID-19 survivors.

Methods

We performed a nationwide retrospective cohort study in Mexico, including adults (aged 20 years or above) with laboratory-confirmed COVID-19 (quantitative reverse transcription-polymerase chain reaction, RT-qPCR) COVID-19 by SARS-COV-2. This analysis took place in September 2020, and a broader description of the methods has already been published [4]. Adults whose symptoms appeared from March to June 2020 and who recovered to primary infection, were analyzed. The primary binary outcome was symptomatic reinfection of SARS-COV-2 and was defined by the reappearance of symptoms of COVID-19 at 28 days or more after initial illness [5] and a positive RT-qPCR result. Risk ratios (RR) and 95% confidence intervals (CI), calculated using linear regression models, were used to identify factors associated with the risk of reinfection.

Results

Data from 99,993 participants were analyzed and the overall risk of SARS-COV-2 symptomatic reinfection was 0.21% ($n = 210$). An RT-qPCR result between both episodes was available for 14 reinfection-positive subjects and all of them were negative.

The mean elapsed days ($\pm$ standard deviation) between COVID-19 episodes were 61.0 ± 31.0 and ranged from 28 to 116. Mild subsequent illness was documented in 169 patients (80.5%) of reinfecting subjects and the observed fatality rate was 4.3%.

Table 1 shows the characteristics of the study sample according to the reinfection status for selected variables. Patients with SARS-COV-2 reinfection were younger and were more likely to be healthcare professionals or other related employments. They were also more likely to have had

milder symptoms at primary disease. They had a significantly higher prevalence of chronic kidney disease or immunosuppression (any cause except type 2 diabetes mellitus or kidney disease).

In multiple analyses (Table 2), increasing age was associated with a reduced risk of reinfection ($RR_{per\ year} = 0.99997$, 95% CI 0.99814-0.99958), as well as those with severe primary illness ($RR = 0.9989$, 95% CI 0.9981-0.9997). Compared with housewives, healthcare workers ($RR = 1.0042$, 95% CI 1.0030-1.0055) and other healthcare-related employees ($RR = 1.0025$, 95% CI 1.0012-1.0039) showed an increased reinfection risk. Other high-risk conditions included the personal history of immunosuppression ($RR = 1.0038$, 95% CI 1.0011 - 1.0065) or chronic kidney disease ($RR = 1.0039$, 95% CI 1.0016-1.0063).

Discussion

Our results suggest that symptomatic SARS-COV-2 reinfection is a rare phenomenon and factors associated with its risk were characterized. However, these results must be carefully considered since currently there is not a well-defined criterion for SARS-COV-2 reinfection [1]. All enrolled subjects reported disappearance of symptoms from primary infection. The used cutout point to identify potential cases of reinfection seemed to be epidemiologically useful since is according to the observed IgG antibodies titers decay in recovered COVID-19 patients [6].

According to our findings, healthcare workers and other related employees (e.g., medical assistants, dentists, etc.) are at increased risk of SARS-COV-2 symptomatic reinfections, which sounds plausible given the increased risk of exposure among these subjects [7]. Mild COVID-19 patients at primary episodes may also be at greater risk of reinfection, which may be secondary to lower antibody titers compared with pneumonia patients [8]. The association between immunosuppression and [2] renal impairment with COVID-19 risk has been widely discussed [4, 9]. If later replicated, further research is needed to identify factors determining a decreased reinfection risk among older participants and after adjusting by multiple exposures. We hypothesize that a reduced COVID-19 awareness among younger subjects may be implied, at least partially.

Conclusions

To the best of our knowledge, this is the first study evaluating predictors of symptomatic SARS-COV-2 reinfection in a large subset of individuals and populations at high-risk were identified. Clinical and epidemiological research regarding SARS-COV-2 reinfection has immediate implications for public health policies focusing on reducing viral spread, including vaccine-related and social-distancing interventions.

Funding

This study was self-funded by the researchers.

Ethical approval

The Health Research Committee 601 of the Mexican Institute of Social Security provided approval (R-2020-601-015).

Conflict of interest

None to declare.

References

1. Tomassini S, Kotecha D, Bird PW, Folwell A, Biju S, Tang JW: **Setting the criteria for SARS-CoV-2 reinfection - six possible cases.** *J Infect* 2020.
2. Kellam P, Barclay W: **The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection.** *J Gen Virol* 2020, **101**(8):791-797.
3. **Government of Mexico. COVID-19 in Mexico: General data. Available at: <https://coronavirus.gob.mx/datos/> (Accessed on September 24, 2020) [Webpage in Spanish].**
4. Murillo-Zamora E, Trujillo X, Huerta M, Rios-Silva M, Mendoza-Cano O: **Male gender and kidney illness are associated with an increased risk of severe laboratory-confirmed coronavirus disease.** *BMC Infect Dis* 2020, **20**(1):674.
5. Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, Niemeyer D, Jones TC, Vollmar P, Rothe C *et al*: **Virological assessment of hospitalized patients with COVID-2019.** *Nature* 2020, **581**(7809):465-469.
6. Seow J, Graham C, Merrick B, Acors S, Steel KJA, Hemmings O, O'Bryne A, Kouphou N, Pickering S, Galao R *et al*: **Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection.** *medRxiv* 2020:2020.2007.2009.20148429.
7. Bielicki JA, Duval X, Gobat N, Goossens H, Koopmans M, Tacconelli E, van der Werf S: **Monitoring approaches for health-care workers during the COVID-19 pandemic.** *Lancet Infect Dis* 2020.
8. Ko JH, Joo EJ, Park SJ, Baek JY, Kim WD, Jee J, Kim CJ, Jeong C, Kim YJ, Shon HJ *et al*: **Neutralizing Antibody Production in Asymptomatic and Mild COVID-19 Patients, in Comparison with Pneumonic COVID-19 Patients.** *J Clin Med* 2020, **9**(7).
9. Thng ZX, De Smet MD, Lee CS, Gupta V, Smith JR, McCluskey PJ, Thorne JE, Kempen JH, Zierhut M, Nguyen QD *et al*: **COVID-19 and immunosuppression: a review of current clinical experiences and implications for ophthalmology patients taking immunosuppressive drugs.** *Br J Ophthalmol* 2020.

Tables

Table 1. Characteristics of the study sample according to symptomatic SARS-COV-2 reinfection status, Mexico 2020

	Overall		SARS-COV-2 reinfection				<i>p</i>
	<i>n</i> = 99,993		No <i>n</i> = 99,783		Yes <i>n</i> = 210		
Gender							
Female	50,916	(50.9)	50,805	(50.9)	111	(52.9)	0.574
Male	49,077	(49.1)	48,978	(49.1)	99	(47.1)	
Age (mean ± SD, years)	42.2 ± 13.1		42.2 ± 13.1		39.2 ± 10.4		< 0.001
Age group (years)							
20-49	73,069	(73.1)	72,888	(73.1)	181	(86.2)	< 0.001
50-59	16,755	(16.8)	16,735	(16.8)	20	(9.5)	
60-69	6,644	(6.6)	6,638	(6.7)	6	(2.9)	
70+	3,525	(3.5)	3,522	(3.5)	3	(1.4)	
Occupation							
Housewife	10,685	(10.7)	10,679	(10.7)	6	(2.9)	< 0.001
Healthcare worker	10,183	(10.2)	10,151	(10.2)	32	(15.2)	
Other healthcare-related	22,303	(22.3)	22,195	(22.2)	108	(51.4)	
Student	919	(0.9)	919	(0.9)	0	(0)	
Other	55,903	(55.9)	55,839	(56.0)	64	(30.5)	
Disease severity (at primary infection) ^a							
Mild - moderate	81,018	(81.0)	80,827	(81.0)	191	(91.0)	< 0.001
Severe	18,975	(19.0)	18,956	(19.0)	19	(9.0)	
<i>Personal history of:</i>							
Obesity (BMI 30 or higher)							
No	81,531	(81.5)	81,353	(81.5)	178	(84.8)	0.228
Yes	18,462	(18.5)	18,430	(18.5)	32	(15.2)	
Type 2 diabetes mellitus							
No	86,909	(86.9)	86,718	(86.9)	191	(91.0)	0.082
Yes	13,084	(13.1)	13,065	(13.1)	19	(9.0)	
Arterial hypertension							
No	82,167	(82.2)	81,991	(82.2)	176	(83.8)	0.535
Yes	17,826	(17.8)	17,792	(17.8)	34	(16.2)	
Immunosuppression ^b							
No	98,830	(98.8)	98,627	(98.8)	203	(96.7)	0.003
Yes	1,163	(1.2)	1,156	(1.2)	7	(3.3)	
Chronic kidney disease							
No	98,440	(98.5)	98,239	(98.5)	201	(95.7)	0.001
Yes	1,553	(1.5)	1,544	(1.5)	9	(4.3)	
Chronic obstructive pulmonary disease							
No	98,872	(98.9)	98,667	(98.9)	205	(97.6)	0.083
Yes	1,121	(1.1)	1,116	(1.1)	5	(2.4)	
Asthma							
No	96,906	(96.9)	96,705	(96.9)	201	(95.7)	0.315
Yes	3,087	(3.1)	3,078	(3.1)	9	(4.3)	
Cancer (any site)							
No	99,744	(99.7)	99,535	(99.7)	209	(99.5)	0.508
Yes	249	(0.3)	248	(0.3)	1	(0.5)	

Abbreviations: **SARS-COV-2**, Severe acute respiratory coronavirus 2; **SD**, Standard deviation; **BMI**, Body mass index.

Notes: 1) The absolute and relative (%) frequencies are presented, except if the mean is specified; 1) *p*-value from chi-square or t-tests are presented as corresponding.

^a Severe illness included the register of dyspnea requiring hospital admission.

^b Immunosuppression referred to any cause of the related deficiency except for type 2 diabetes mellitus or renal impairment.

Table 2. Predictors of symptomatic laboratory-confirmed SARS-COV-2 reinfection, Mexico 2020

	RR (95% CI), <i>p</i>					
	Bivariate analysis			Multiple analysis		
Gender						
Female	1.0000			1.0000		
Male	0.9998	(0.9993 - 1.0004)	0.574	1.0004	(0.9997 - 1.0009)	0.256
Age group (years)						
20-49	1.0000			1.0000		
50-59	0.9987	(0.9980 - 0.9995)	0.001	0.9989	(0.9981 - 0.9997)	0.006
60-69	0.9984	(0.9973 - 0.9996)	0.007	0.9984	(0.9972 - 0.9996)	0.009
70+	0.9983	(0.9968 - 0.9999)	0.039	0.9982	(0.9966 - 0.9999)	0.032
Occupation						
Housewife	1.0000			1.0000		
Healthcare worker	1.0043	(1.0032 - 1.0054)	< 0.001	1.0042	(1.0030 - 1.0055)	< 0.001
Other healthcare-related	1.0026	(1.0013 - 1.0038)	< 0.001	1.0025	(1.0012 - 1.0039)	< 0.001
Student	0.9994	(0.9964 - 1.0025)	0.721	0.9993	(0.9961 - 1.0024)	0.646
Other	1.0006	(0.9996 - 1.0015)	0.227	1.0005	(0.9994 - 1.0016)	0.337
Disease severity (at primary infection) ^a						
Mild - moderate	1.0000			1.0000		
Severe	0.9987	(0.9979 - 0.9994)	< 0.001	0.9989	(0.9981 - 0.9997)	0.007
<i>Personal history of:</i>						
Obesity (BMI 30 or higher)						
No	1.0000			1.0000		
Yes	0.9996	(0.9988 - 1.0003)	0.228	0.9997	(0.9989 - 1.0004)	0.360
Type 2 diabetes mellitus						
No	1.0000			1.0000		
Yes	0.9993	(0.9984 - 1.0001)	0.082	0.9996	(0.9987 - 1.0005)	0.333
Immunosuppression ^b						
No	1.0000			1.0000		
Yes	1.0040	(1.0013 - 1.0066)	0.003	1.0038	(1.0011 - 1.0065)	0.005
Chronic kidney disease						
No	1.0000			1.0000		
Yes	1.0038	(1.0015 - 1.0061)	0.001	1.0039	(1.0016 - 1.0063)	0.001

Abbreviations: **RR**, Risk ratio; **CI**, Confidence interval; **BMI**, Body mass index.

Notes: 1) Generalized linear regression models were used to obtain RR and 95% CI; 2) Multiple regression coefficients were adjusted by variables listed in the table.

^a Severe illness included the register of dyspnea requiring hospital admission.

^b Immunosuppression referred to any cause of the related deficiency except for type 2 diabetes mellitus or renal impairment.